DHFR and malaria: Although inhibitors of the dihydrofolate reductase (DHFR, catalyzing the hydration of folic acid to di- and tetrahydro folic acid) are successfully used in therapy, e.g., malaria [11], Leishmania species show resistance against common antifolates such as methotrexate (MTX).